CAG
NVO

Cypress Advisory Group’s Novo Nordisk NVO Stock Holding History

Cypress Advisory Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,300
Closed -$228K – 68
2025
Q2 		$228K Hold
3,300
– – 0.18% 66
2025
Q1 		$229K Hold
3,300
– – 0.21% 58
2024
Q4 		$284K Buy
+3,300
New +$357K 0.26% 54

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cypress Advisory Group's NVO Position: Q3 2025 in Review

Cypress Advisory Group sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,300 shares — an estimated $228K sold.

Cypress Advisory Group first reported a position in NVO in Q4 2024 and held it in 3 quarters. The position peaked at $284K in Q4 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Cypress Advisory Group reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Cypress Advisory Group sold 3,300 Novo Nordisk shares in Q3 2025, an estimated $228K.
  • Cypress Advisory Group first reported a position in Novo Nordisk in Q4 2024 and held it in 3 quarters.
  • Cypress Advisory Group's Novo Nordisk position peaked at $284K in Q4 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Cypress Advisory Group's 13F filing for Q3 2025, filed 29 Oct 2025.